Reshape Lifesciences INC S-1 registration statements

ReShape Lifesciences has filed a registration statement to register an additional $9,152,802 in securities, including common stock and warrants.

ReShape Lifesciences is launching a best-efforts offering of up to 1,779,360 units, each containing a share of common stock or a pre-funded warrant and a warrant, aiming to raise capital for general corporate purposes including merger expenses.

ReShape Lifesciences is seeking to raise capital through a unit offering to fund operations while it awaits the closing of its merger with Vyome Therapeutics and the sale of its assets to Ninjour Health International.

ReShape Lifesciences details the terms of common stock purchase warrants and a merger agreement with Vyome Therapeutics, outlining exercise conditions, price adjustments, and potential alternative considerations.

ReShape Lifesciences files an amendment to its registration statement for the resale of common stock by Ascent Partners Fund LLC, as the company navigates a proposed merger with Vyome Therapeutics and asset sale to Ninjour Health International Limited.

ReShape Lifesciences is undertaking a best-efforts unit offering to raise capital while navigating a pending merger and asset sale.

ReShape Lifesciences Inc. has filed a registration statement for a potential offering of up to $3.5 million in common stock, as the company navigates a proposed merger and asset sale.

ReShape Lifesciences has filed an amendment to its S-1 registration statement, detailing the potential resale of up to 2,112,072 shares of common stock by a selling stockholder.

Reshape Lifesciences has entered into an equity purchase agreement with Ascent Partners Fund, providing access to up to $5 million in funding through the sale of common stock.